Summary
On mountain emergencies...Sapna's had them, James denies them...This conversation delves into the treatment options available for patients with advanced melanoma who have progressed after anti PD-1 therapy. The discussion covers various clinical studies, response rates, and the implications of combination therapy post-PD1 progression. James and Sapna conclude that while combination therapies show promise, the responses may not be as robust as those seen in frontline treatments.
Keywords
melanoma, PD-1, treatment, clinical trials, immunotherapy, BRAF, response rates, efficacy, combination therapy, patient outcomes
Takeaways
The conversation focuses on treatment options after PD-1 progression.
Clinical studies provide valuable data on post-PD-1 therapies.
Response rates for combination therapies are generally higher than monotherapy.
BRAF status is a critical factor in treatment decisions.
Randomized studies help clarify the efficacy of different treatment approaches.
Combination therapy may offer better outcomes for patients post-PD-1.
Acquired resistance remains a challenge.
Titles
Exploring Treatment Options Beyond PD-1
The Role of Clinical Trials in Melanoma Therapy
Sound Bites
"What to do post PD-1 exposure?"
"Can you get a response to IPI after PD-1?"
"The primary endpoint was PFS, not ORR... "
Chapters
00:00 Opening theme music (My Favourite Dress by The Wedding Present)
01:25 Mountain rescue quickfire
03:08 Post anti-PD1 studies - the issues
04:13 Pires da Silva retrospective study
08:53 Olson single-arm prospective study (and yes we see you Jason)
10:38 SWOG S1616 randomized ph 2 study
16:35 Conclusions
17:17 Fact Check